No need to suffer heartburn after a heart attack
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Although proton pump inhibitors do have a negative influence on the antiplatelet effects of clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis' Plavix) and prasugrel (Lilly/Daiichi Sankyo's Effient), the antacids don't appear to interfere with the clinical outcome for patients, according to an analysis of data from the TIMI-44 and TIMI-38 trials presented Sept. 1 at the European Society of Cardiology congress. The antacids are thought to inhibit the conversion of the thienopyridine class drugs into active form in the body, and the drug-drug interaction has sparked safety warnings from both FDA and EMEA. Professional guidelines, however, still recommend administering PPIs with the antiplatelet drugs to help reduce the risk of gastrointestinal bleeding. AstraZeneca's experimental antiplatelet drug Brilinta (ticagrelor), for which positive Phase III data was presented at ESC, may offer a solution to the interaction dilemma if it is approved as anticipated in 2010. Ticagrelor has a different mechanism of action from clopidogrel or prasugrel; it is an active compound that does not require bioactivation (1"The Pink Sheet," Sept. 7, 2009)
You may also be interested in...
AstraZeneca's Ticagrelor Brilliant At ECS Congress; Will It Outshine Effient?
The comparator in AstraZeneca's PLATO trial for its antiplatelet candidate Brilinta (ticagrelor) was clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis' Plavix) but the real test for the product, should it reach the market, may be against Eli Lilly/Daiichi Sankyo's recently approved Effient (prasugrel)
'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: